Pseudoprogression as an adverse event of glioblastoma therapy

We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Balaña, Carmen, Capellades, Jaume, Pineda, Estela, Estival, Anna, Puig, Josep, Domenech, Sira, Verger, Eugenia, Pujol, Teresa, Martinez‐García, Maria, Oleaga, Laura, Velarde, JoseMaria, Mesia, Carlos, Fuentes, Rafael, Marruecos, Jordi, Del Barco, Sonia, Villà, Salvador, Carrato, Cristina, Gallego, Oscar, Gil‐Gil, Miguel, Craven‐Bartle, Jordi, Alameda, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727237/
https://www.ncbi.nlm.nih.gov/pubmed/29105360
http://dx.doi.org/10.1002/cam4.1242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727237/
https://www.ncbi.nlm.nih.gov/pubmed/29105360
http://dx.doi.org/10.1002/cam4.1242

Ejemplares similares